Pivotal readout
Sinovent's funobactam combination matches relebactam regimen in hospital pneumonia
A phase 3 double-blind trial of Sinovent's imipenem-cilastatin-funobactam in hospital-acquired and ventilator-associated bacterial pneumonia has been published in a leading infectious disease journal. The combination was non-inferior to imipenem-cilastatin-relebactam on 14-day all-cause mortality, with good tolerability. Sinovent positions it as a domestic option against carbapenem-resistant Gram-negative bacteria.
- Drugimipenem
- Drugcilastatin
- Drugpibozobactam
- CompanySinovent
- TargetPenicillin-binding protein 1A
- TargetPenicillin-binding protein 1B
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.